| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
,
*
University of California, Los Angeles, Medical School-Wadsworth Pulmonary Laboratory, Veterans Administration West Los Angeles Healthcare Center,
Jonsson Comprehensive Cancer Center, and
Division of Pulmonary and Critical Care Medicine, University of California, Los Angeles, Medical School, Los Angeles, CA 90073
Secondary lymphoid tissue chemokine (SLC, also referred to as
Exodus 2 or 6Ckine) is a recently identified high endothelial-derived
CC chemokine. The ability of SLC to chemoattract both Th1 lymphocytes
and dendritic cells formed the rationale to evaluate this chemokine in
cancer immunotherapy. Intratumoral injection of recombinant SLC
evidenced potent antitumor responses and led to complete tumor
eradication in 40% of treated mice. SLC-mediated antitumor responses
were lymphocyte dependent as evidenced by the fact that this therapy
did not alter tumor growth in SCID mice. Studies performed in CD4 and
CD8 knockout mice also revealed a requirement for both CD4 and CD8
lymphocyte subsets for SLC-mediated tumor regression. In
immunocompetent mice, intratumoral SLC injection led to a significant
increase in CD4 and CD8 T lymphocytes and dendritic cells, infiltrating
both the tumor and the draining lymph nodes. These cell infiltrates
were accompanied by the enhanced elaboration of Th1 cytokines and
chemokines monokine induced by IFN-
and IFN--inducible protein 10
but a concomitant decrease in immunosuppressive cytokines at the tumor
site. In response to irradiated autologous tumor, splenic and lymph
node-derived cells from SLC-treated tumor-bearing mice secreted
significantly more IFN-, GM-CSF, and IL-12 and reduced levels of
IL-10 than did diluent-treated tumor-bearing mice. After stimulation
with irradiated autologous tumor, lymph node-derived lymphocytes from
SLC-treated tumor-bearing mice demonstrated enhanced cytolytic
capacity, suggesting the generation of systemic immune responses. These
findings provide a strong rationale for further evaluation of SLC in
tumor immunity and its use in cancer
immunotherapy.
This article has been cited by other articles:
|
|
 |
|
  C.-m. Liang, C.-p. Zhong, R.-x. Sun, B.-b. Liu, C. Huang, J. Qin, S. Zhou, J. Shan, Y.-k. Liu, and S.-l. Ye Local Expression of Secondary Lymphoid Tissue Chemokine Delivered by Adeno-Associated Virus within the Tumor Bed Stimulates Strong Anti-Liver Tumor Immunity J. Virol., September 1, 2007; 81(17): 9502 - 9511. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Novak, O. Igoucheva, S. Cho, and V. Alexeev Characterization of the CCL21-mediated melanoma-specific immune responses and in situ melanoma eradication Mol. Cancer Ther., June 1, 2007; 6(6): 1755 - 1764. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-C. Yang, R. K. Batra, S. Hillinger, K. L. Reckamp, R. M. Strieter, S. M. Dubinett, and S. Sharma Intrapulmonary Administration of CCL21 Gene-Modified Dendritic Cells Reduces Tumor Burden in Spontaneous Murine Bronchoalveolar Cell Carcinoma. Cancer Res., March 15, 2006; 66(6): 3205 - 3213. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Pan, M. D. Burdick, J. A. Belperio, Y. Y. Xue, C. Gerard, S. Sharma, S. M. Dubinett, and R. M. Strieter CXCR3/CXCR3 Ligand Biological Axis Impairs RENCA Tumor Growth by a Mechanism of Immunoangiostasis J. Immunol., February 1, 2006; 176(3): 1456 - 1464. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Sharma, L. Zhu, S. C. Yang, L. Zhang, J. Lin, S. Hillinger, B. Gardner, K. Reckamp, R. M. Strieter, M. Huang, et al. Cyclooxygenase 2 Inhibition Promotes IFN-{gamma}-Dependent Enhancement of Antitumor Responses J. Immunol., July 15, 2005; 175(2): 813 - 819. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Zhang, R. Somasundaram, K. Berencsi, L. Caputo, P. Rani, D. Guerry, E. Furth, B. J. Rollins, M. Putt, P. Gimotty, et al. CXC Chemokine Ligand 12 (Stromal Cell-Derived Factor 1{alpha}) and CXCR4-Dependent Migration of CTLs toward Melanoma Cells in Organotypic Culture J. Immunol., May 1, 2005; 174(9): 5856 - 5863. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Xiang, N. Mizutani, Y. Luo, C. Chiodoni, H. Zhou, M. Mizutani, Y. Ba, J. C. Becker, and R. A. Reisfeld A DNA Vaccine Targeting Survivin Combines Apoptosis with Suppression of Angiogenesis in Lung Tumor Eradication Cancer Res., January 15, 2005; 65(2): 553 - 561. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Chun, C.-C. Yin, J.-Z. Song, M.-X. Liu, J.-H. Piao, Q. Lin, X.-B. Wang, and H.-L. Huang Soluble Expression of Recombinant Human Secondary Lymphoid Chemokine (SLC) in E. coli and Research on Its In Vitro and In Vivo Bioactivity J. Biochem., December 1, 2004; 136(6): 769 - 776. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Treilleux, J.-Y. Blay, N. Bendriss-Vermare, I. Ray-Coquard, T. Bachelot, J.-P. Guastalla, A. Bremond, S. Goddard, J.-J. Pin, C. Barthelemy-Dubois, et al. Dendritic Cell Infiltration and Prognosis of Early Stage Breast Cancer Clin. Cancer Res., November 15, 2004; 10(22): 7466 - 7474. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-F. He, G.-M. Zhang, X.-H. Wang, H. Zhang, Y. Yuan, D. Li, and Z.-H. Feng Blocking Programmed Death-1 Ligand-PD-1 Interactions by Local Gene Therapy Results in Enhancement of Antitumor Effect of Secondary Lymphoid Tissue Chemokine J. Immunol., October 15, 2004; 173(8): 4919 - 4928. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Lavergne, C. Combadiere, M. Iga, A. Boissonnas, O. Bonduelle, M. Maho, P. Debre, and B. Combadiere Intratumoral CC Chemokine Ligand 5 Overexpression Delays Tumor Growth and Increases Tumor Cell Infiltration J. Immunol., September 15, 2004; 173(6): 3755 - 3762. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-C. Yang, S. Hillinger, K. Riedl, L. Zhang, L. Zhu, M. Huang, K. Atianzar, B. Y. Kuo, B. Gardner, R. K. Batra, et al. Intratumoral Administration of Dendritic Cells Overexpressing CCL21 Generates Systemic Antitumor Responses and Confers Tumor Immunity Clin. Cancer Res., April 15, 2004; 10(8): 2891 - 2901. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Hillinger, S.-C. Yang, L. Zhu, M. Huang, R. Duckett, K. Atianzar, R. K. Batra, R. M. Strieter, S. M. Dubinett, and S. Sharma EBV-Induced Molecule 1 Ligand Chemokine (ELC/CCL19) Promotes IFN-{gamma}-Dependent Antitumor Responses in a Lung Cancer Model J. Immunol., December 15, 2003; 171(12): 6457 - 6465. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Tolba, W. J. Bowers, J. Muller, V. Housekneckt, R. E. Giuliano, H. J. Federoff, and J. D. Rosenblatt Herpes Simplex Virus (HSV) Amplicon-mediated Codelivery of Secondary Lymphoid Tissue Chemokine and CD40L Results in Augmented Antitumor Activity Cancer Res., November 15, 2002; 62(22): 6545 - 6551. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. W. Christopherson II, J. J. Campbell, J. B. Travers, and R. A. Hromas Low-Molecular-Weight Heparins Inhibit CCL21-Induced T Cell Adhesion and Migration J. Pharmacol. Exp. Ther., July 1, 2002; 302(1): 290 - 295. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Luther, A. Bidgol, D. C. Hargreaves, A. Schmidt, Y. Xu, J. Paniyadi, M. Matloubian, and J. G. Cyster Differing Activities of Homeostatic Chemokines CCL19, CCL21, and CXCL12 in Lymphocyte and Dendritic Cell Recruitment and Lymphoid Neogenesis J. Immunol., July 1, 2002; 169(1): 424 - 433. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. W. Christopherson II, J. J. Campbell, and R. A. Hromas Transgenic overexpression of the CC chemokine CCL21 disrupts T-cell migration Blood, December 15, 2001; 98(13): 3562 - 3568. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Sharma, M. Stolina, L. Zhu, Y. Lin, R. Batra, M. Huang, R. Strieter, and S. M. Dubinett Secondary Lymphoid Organ Chemokine Reduces Pulmonary Tumor Burden in Spontaneous Murine Bronchoalveolar Cell Carcinoma Cancer Res., September 1, 2001; 61(17): 6406 - 6412. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Christopherson II and R. Hromas Chemokine Regulation of Normal and Pathologic Immune Responses Stem Cells, September 1, 2001; 19(5): 388 - 396. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Hjelmström Lymphoid neogenesis: de novo formation of lymphoid tissue in chronic inflammation through expression of homing chemokines J. Leukoc. Biol., March 1, 2001; 69(3): 331 - 339. [Abstract] [Full Text]
|
|
|
|
|
|
C. J. Kirk, D. Hartigan-O’Connor, B. J. Nickoloff, J. S. Chamberlain, M. Giedlin, L. Aukerman, and J. J. Mulé T Cell-dependent Antitumor Immunity Mediated by Secondary Lymphoid Tissue Chemokine: Augmentation of Dendritic Cell-based Immunotherapy Cancer Res., March 1, 2001; 61(5): 2062 - 2070. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
